AU725585B2 - 1-(1H-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor - Google Patents

1-(1H-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor Download PDF

Info

Publication number
AU725585B2
AU725585B2 AU31689/97A AU3168997A AU725585B2 AU 725585 B2 AU725585 B2 AU 725585B2 AU 31689/97 A AU31689/97 A AU 31689/97A AU 3168997 A AU3168997 A AU 3168997A AU 725585 B2 AU725585 B2 AU 725585B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
pyrrol
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31689/97A
Other languages
English (en)
Other versions
AU3168997A (en
Inventor
Hugo Alfons Gabriel Geerts
Johan Jozef Gustave Hendrik Geysen
Michael Joseph Kukla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU3168997A publication Critical patent/AU3168997A/en
Application granted granted Critical
Publication of AU725585B2 publication Critical patent/AU725585B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU31689/97A 1996-05-31 1997-05-26 1-(1H-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor Ceased AU725585B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201501 1996-05-31
EP96201501 1996-05-31
PCT/EP1997/002775 WO1997046552A1 (en) 1996-05-31 1997-05-26 1-(1h-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor

Publications (2)

Publication Number Publication Date
AU3168997A AU3168997A (en) 1998-01-05
AU725585B2 true AU725585B2 (en) 2000-10-12

Family

ID=8224030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31689/97A Ceased AU725585B2 (en) 1996-05-31 1997-05-26 1-(1H-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor

Country Status (8)

Country Link
US (1) US6054468A (OSRAM)
EP (1) EP0906305A1 (OSRAM)
JP (1) JP2000511549A (OSRAM)
KR (1) KR20000010698A (OSRAM)
AU (1) AU725585B2 (OSRAM)
CA (1) CA2254757A1 (OSRAM)
NZ (1) NZ332545A (OSRAM)
WO (1) WO1997046552A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5600100A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6500844B1 (en) 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6358979B1 (en) 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
US6472410B1 (en) 1999-06-11 2002-10-29 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2000076513A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
AU5469400A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US7012100B1 (en) * 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US20030236290A1 (en) * 2002-06-12 2003-12-25 Gabriel Fenteany Inhibitors of animal cell motility and growth
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510944D0 (en) * 1995-05-31 1995-07-26 Bogaert Thierry Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour

Also Published As

Publication number Publication date
US6054468A (en) 2000-04-25
NZ332545A (OSRAM) 2000-01-28
CA2254757A1 (en) 1997-12-11
AU3168997A (en) 1998-01-05
WO1997046552A1 (en) 1997-12-11
KR20000010698A (ko) 2000-02-25
JP2000511549A (ja) 2000-09-05
EP0906305A1 (en) 1999-04-07

Similar Documents

Publication Publication Date Title
US7550465B2 (en) Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
DE69528257T2 (de) KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, DEREN HERSTELLUNG UND VERWENDUNG ALS GnRH ANTAGONISTEN
EP2438067B1 (de) Spirolactame als cgrp-antagonisten
JPH10509150A (ja) 酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ
HK18194A (en) Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
JP2005529953A (ja) アスパルチルプロテアーゼインヒビター
IE872173L (en) Piperidine compounds.
US6054468A (en) 1-(1H-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor
JP2004506687A (ja) メラノコルチン受容体作働薬としての置換ピペリジン類
JP2003534377A (ja) メラノコルチン受容体作働薬
JP2011504892A (ja) ホスホジエステラーゼ１０の阻害剤としてのアリール及びヘテロアリール縮合イミダゾ（１，５−ａ）ピラジン
EP2605771B1 (en) Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
WO2009068246A2 (en) Methods of treating obesity and metabolic disorders
US20040147454A1 (en) Aspartyl protease inhibitors
JPH09151174A (ja) ベンゾニトリル類およびベンゾフルオリド類
DE60222286T2 (de) Verfahren zur erhöhung des testosteronspiegels
EP1056771B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
US20240148743A1 (en) Uses of melanocortin-4 receptor agonist
DE69829849T2 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
WO2012093859A2 (ko) 폴리사이클릭 펩타이드 화합물을 포함하는 항균용 조성물 및 이의 생산방법
JP2941702B2 (ja) ５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物
US20050026937A1 (en) 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US6080756A (en) Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin
MX2012006739A (es) Profarmacos de [4 [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il] -(1h-pirrolo-piridin-il)-metanonas y sintesis de estos.
EP0840609B1 (en) Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)